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Abstract: Bronchodilators provide the mainstay of pharmacologic therapy for chronic 
  obstructive pulmonary disease (COPD), and anticholinergic bronchodilators, in particular, appear 
to be the most effective. There are currently two anticholinergic agents available in the US for 
the treatment of COPD (ipratropium bromide and tiotropium bromide), but several others are 
in various stages of development. Aclidinium bromide, a novel, long-acting, anticholinergic 
bronchodilator, is currently in Phase III trials for the management of COPD. Available evidence 
suggests that aclidinium is a safe and well tolerated drug with a relatively rapid onset and a 
sufficient duration of action to provide once-daily dosing. This article will provide a pharma-
cologic profile of aclidinium bromide and review the preclinical and clinical studies evaluating 
its safety and efficacy in the treatment of COPD.
Keywords: aclidinium bromide, bronchodilators, pulmonary disease, chronic obstructive, 
muscarinic antagonists, pharmacokinetics, pharmacology
Introduction
Chronic obstructive pulmonary disease (COPD) is characterized, in part, by chronic 
airflow limitation that is not fully reversible and is associated with an abnormal 
inflammatory response of the lung to inhaled noxious particles or gases.1 The airflow 
obstruction in COPD is multifactorial, with contributions from narrowing of the small 
airways due to inflammatory exudates, wall thickening, and mucus hypersecretion,2 
small airway collapsibility due to loss of tethering forces surrounding the airway,3 and 
increased bronchomotor tone.4 Bronchodilators target this last mechanism and provide 
the mainstay of pharmacologic therapy in COPD. In particular, anticholinergic agents 
appear to be the most effective bronchodilators in the management of COPD.5–7 There 
are currently two anticholinergic agents available in the US for the treatment of COPD 
(ipratropium bromide and tiotropium bromide), but several others are in various stages 
of development. Aclidinium bromide, a novel, long-acting, anticholinergic broncho-
dilator, is currently in Phase III trials for the management of COPD. This article will 
provide a pharmacologic profile of aclidinium bromide and review the preclinical and 
clinical studies evaluating its safety and efficacy in the treatment of COPD.
Rationale for development of new anticholinergic 
drugs for COPD
There are five subtypes of muscarinic acetylcholine receptors (M1–5), but only M1, M2, 
and M3 are expressed in human lung tissue (see Figure 1).8 M1 receptors are primar-
ily found in parasympathetic ganglia and facilitate neurotransmission. M2 receptors International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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are expressed both on presynaptic parasympathetic nerve 
endings at the neuromuscular junction, providing feedback 
inhibition of acetylcholine release, and on bronchial smooth 
muscle, where M2 receptors counteract bronchodilatation by 
inhibiting beta-2 receptor-mediated cyclic AMP production.9 
Thus, M2 receptor stimulation can both inhibit and promote 
bronchoconstriction depending on the site of stimulation. M2 
receptors in the heart evoke parasympathetic decreases in 
heart rate. M3 receptors are expressed on bronchial smooth 
muscle, submucosal mucus glands, and vascular endothe-
lium in the lung, where they mediate bronchoconstriction, 
mucus secretion, and vasodilation, respectively. Interestingly, 
although M2 receptors outnumber M3 receptors on bronchial 
smooth muscle by about a 4:1 ratio, M3 receptors predomi-
nantly control bronchomotor tone.9 M 3 receptors are also 
found in the gut, urinary bladder, eyes, and salivary glands 
and are thought to be the predominant receptor mediating 
parasympathetic gut and urinary bladder motility, miosis, 
and salivation.
Parasympathetic activity is amplified in COPD and pro-
motes M3 receptor-mediated bronchomotor tone, representing 
the dominant reversible component of airflow obstruction in 
those with the disease.10 In addition, M3 receptor stimulation 
contributes significantly to mucus hypersecretion in many 
patients with COPD. Anticholinergic agents thus provide 
an important target for the treatment of COPD. Although 
clinical studies of anticholinergic agents have failed to show 
consistent reduction in mucus production, such agents have 
provided superior bronchodilatation to beta-agonists in 
subjects with COPD.6,7
Ipratropium bromide, a nonselective muscarinic recep-
tor antagonist, has been used in the treatment of COPD for 
decades, and remains an important part of the pharmacologic 
armamentarium. The development of tiotropium bromide, 
however, has represented an important advance in anticho-
linergic therapy, and this drug has two main advantages over 
ipratropium. First, tiotropium has a much longer duration 
of action than ipratropium, allowing once-daily dosing in 
comparison with four times daily with ipratropium. Second, 
tiotropium exhibits a kinetic selectivity for the M3 receptor 
over the M2 receptor,11 which preserves efficacy as a bron-
chodilator and decreases the risk of M2-mediated cardiac side 
effects. The cardiovascular safety profile of anticholinergic 
agents has been questioned, and a recent meta-analysis 
suggested a higher rate of cardiovascular complications 
among those taking anticholinergic drugs.12 In contrast, the 
Understanding Potential Long-term Impacts on Function with 
Tiotropium (UPLIFT) trial demonstrated that the tiotropium 
group had a lower likelihood of cardiovascular adverse events, 
and in particular a lower rate of myocardial infarction, rela-
tive to placebo.13 The much longer half-life of tiotropium at 
the M3 receptor relative to its half-life at the M2 receptor in 
contrast with the relatively short residence of ipratropium at 
both receptors may explain this discrepancy.
Although tiotropium has established clinical benefits and 
is generally well tolerated,13 anticholinergic side effects are 
occasionally seen, including dry mouth, constipation, tachy-
cardia, blurry vision, new onset or worsening of narrow-angle 
glaucoma, and urinary retention or infection.14 Systemic 
absorption of inhaled tiotropium is relatively limited, with 
only 14% of an inhaled dose being excreted in the urine and 
the remainder being nonabsorbed drug eliminated via the 
feces. However, 74% of an intravenously administered dose 
is excreted unchanged in the urine, and renal impairment is 
associated with increased plasma concentrations and reduced 
clearance of tiotropium after both intravenous and inhaled 
administration.14 As a result, renal impairment increases 
systemic drug exposure and may increase the likelihood of 
anticholinergic side effects.14,15 Importantly, clinical trials, 
which often exclude patients with significant renal impair-
ment, may underestimate the prevalence of anticholinergic 
side effects when used in a more generalized population.
The success of tiotropium in the treatment of COPD has 
led to vigorous investigation in search of novel anticholin-
ergic agents that share some of the beneficial characteristics 
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Figure 1 Muscarinic receptor subtypes in the human airway. 
Reproduced with permission. Barnes PJ. The role of anticholinergics in chronic 
obstructive pulmonary disease. Am J Med. 2004;117 Suppl 12A:24S–32S. 
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of tiotropium and perhaps improve upon less desirable ones. 
Aclidinium bromide (previously known as LAS34273) is 
a novel muscarinic antagonist developed by Almirall SA 
  (Barcelona, Spain). The US Food and Drug Administration 
has not yet approved aclidinium for clinical use, but it is 
currently undergoing Phase III investigation for the treat-
ment of COPD. Early preclinical and clinical studies suggest 
some promise for this drug, with significant and long-lasting 
bronchodilator effects and a very favorable safety profile.
Pharmacology and 
pharmacokinetics
Composition
The chemical designation of aclidinium bromide is (3R)-
3-y-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2] octane 
bromide, and it is a quaternary ammonium derivative of a 
(3R)-  quinuclidinol ester (see Figure 2). Aclidinium was devel-
oped by Almirall SA among a series of muscarinic antagonists 
and selected for further development on the basis of its high 
binding affinity for the M3 receptor, long duration of action, and 
preliminary safety profile.16 As with tiotropium, quaternization 
of its tertiary amino function imparts a low oral bioavailability 
and low blood-brain barrier permeability,16 thereby reducing 
systemic exposure, especially via the inhaled route.
Receptor binding affinity and kinetics
Aclidinium is a very potent inhibitor of muscarinic receptors 
with subnanomolar affinity for all receptor subtypes (M1–5).17 
However, like tiotropium, aclidinium dissociates more slowly 
from the M3 receptor than it does from the M2 receptor, with 
an M3 half-life that is approximately six times that of its 
M2 half-life.17,18 Accordingly, aclidinium, like tiotropium, 
will yield bronchodilation via M3 blockade long after its 
less desirable M2 effects, such as tachycardia, diminish. 
In addition, preclinical studies suggest that aclidinium has 
an onset of action that is faster than tiotropium and almost 
as fast as ipratropium.17,19
Drug delivery and distribution
Aclidinium is a dry powder formulation delivered by a novel, 
multidose, breath-actuated dry powder device called the 
Genuair® inhaler.20 Unlike the HandiHaler® used to deliver 
tiotropium, which must be loaded by hand with a capsule 
daily, the Genuair inhaler is preloaded with a one-month 
supply of aclidinium powder. After removing the cap on the 
mouthpiece, the patient must press and release a button on 
the top of the inhaler to load a single dose into the inhalation 
chamber. A colored control window simultaneously turns 
from red to green, indicating that the inhaler is ready for use. 
The patient is then instructed to inhale as fast and as deep as 
possible through the mouthpiece to release the dose, followed 
by a 10 second breath hold. Several feedback mechanisms 
may help to indicate appropriate use, including an audible 
click, a slightly sweet taste perceived by some but not all 
patients, and change in the colored control window from 
green back to red with an adequate inhalation. To prevent 
accidental overdose, a trigger lockout prevents loading of an 
additional dose into the inhalation chamber until a successful 
inhalation has occurred.
As with other dry powder inhalers, the inspiratory flow 
required to generate adequate powder aerosolization for the 
Genuair inhaler is quite high (45 L/min or more).21 Recent 
evidence suggests that elderly patients and those with moder-
ate to severe COPD may have difficulty generating sufficient 
inspiratory flow for correct use of dry powder inhalers.22,23 
This appears to be a particularly relevant issue for the Handi-
Haler device for delivery of tiotropium, where, in one study, 
as many as 24% of patients with moderate to severe airflow 
obstruction were unable to achieve the minimum required 
peak inspiratory flow of $20 L/min.14,22 Because the peak 
inspiratory flow generated through a dry powder inhaler is 
inversely proportional to its resistance,24 devices with a higher 
resistance require greater effort on the part of the patient to 
achieve adequate inspiratory flow for effective aerosolization. 
Not surprisingly, the HandiHaler device manifests one of the 
highest resistances among the dry powder inhalers.22 In con-
trast, the Genuair inhaler exhibits a relatively low resistance, 
and patients with moderate to severe COPD were able to 
achieve adequate inhalations ($45 L/min) 97% of the time 
with average peak inspiratory flows of 92.0 ± 15.4 L/min. 
Whether improved drug aerosolization due to higher peak 
inspiratory flows will translate into greater efficacy in the 
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Figure 2 Chemical structure of aclidinium bromide. 
Reproduced with permission. Gavalda A, Miralpeix M, Ramos I, et al. Characteri­
zation  of  aclidinium  bromide,  a  novel  inhaled  muscarinic  antagonist,  with  long 
duration of action and a favorable pharmacological profile. J Pharmacol Exp Ther. 
2009;331(2):740–751.17
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treatment of elderly patients with moderate to severe COPD, 
however, remains unproven.
Studies using a radiolabeled drug preparation have 
demonstrated that approximately 30% of the metered dose 
of aclidinium (34% of the delivered dose) is distributed to 
the lungs in healthy subjects via the Genuair inhaler,20 com-
pared with 18% of the metered dose of tiotropium (43% of 
the delivered dose) via the HandiHaler device.25 Though this 
comparison reflects the relative efficiencies of the delivery 
devices, it is likely irrelevant to clinical efficacy of the drugs 
themselves given that the metered dose selected for devel-
opment accounts for the fraction delivered to the lung and 
pharmacodynamic effects.
A more relevant result of radiolabeling studies in terms of 
drug efficacy may be the distribution of the drug within the 
lung. However, a comparison of the effectiveness of short-
acting bronchodilators with differing aerosol particle sizes 
suggests that delivery to the smaller, more peripheral airways 
may be less important for anticholinergic agents than it is 
for beta-agonists,26 likely because the density of muscarinic 
receptors is thought to be higher in the central airways than 
in the peripheral airways.27 Both aclidinium and tiotropium 
are deposited preferentially within the central airways relative 
to the peripheral airways, in keeping with the distribution of 
muscarinic receptors.20,25
Metabolism
Due to their quaternary ammonium functions, all mus-
carinic antagonists are poorly absorbed into the plasma 
following inhaled delivery. Nonetheless, at least some of 
each compound is absorbed, leading to the potential for 
extrapulmonary side effects. However, in contrast with 
both ipratropium and tiotropium, aclidinium has a very 
short plasma half-life. Initial studies of aclidinium dem-
onstrated a plasma half-life of 2.2 minutes, compared with 
more than 60 minutes for both ipratropium and tiotropium.16 
Additional studies demonstrated that aclidinium, like ipra-
tropium and tiotropium, undergoes rapid hydrolysis into 
two major metabolites, a carboxylic acid derivative and an 
alcohol derivative, neither of which have any affinity for 
any of the muscarinic receptor subtypes.28 This study also 
showed that nonenzymatic hydrolysis of aclidinium occurs 
at physiologic pH, but at a rate inadequate to explain its 
short plasma half-life, suggesting the presence of enzy-
matic hydrolysis in plasma. Subsequent work confirmed 
that butyrylcholinesterase is the primary enzyme involved 
in the hydrolysis of aclidinium and that this process takes 
place predominantly in the plasma.29
Importantly, because aclidinium undergoes rapid plasma 
hydrolysis into inactive metabolites, very little intact acli-
dinium is excreted in the urine and renal dysfunction does not 
appear to have a significant impact on systemic exposure.30 
In contrast, circulating tiotropium is predominantly excreted 
unchanged in the urine, and renal impairment results in 
increased systemic exposure.15 Although the pharmacoki-
netics of ipratropium have not been studied in patients with 
renal impairment,31 its much shorter receptor binding half-life 
compared with aclidinium and tiotropium would suggest less 
potential for a significant effect of renal dysfunction.
Safety
Early preclinical and clinical studies have suggested a very 
favorable safety profile for aclidinium. Its rapid plasma hydro-
lysis results in minimal to no systemic exposure 15 minutes 
following a dose, suggesting a low potential for extrapulmo-
nary side effects regardless of renal impairment.16,28 In addi-
tion, given that the tachycardia associated with muscarinic 
antagonists results from blockade of M2 receptors in the heart, 
the kinetic selectivity of aclidinium and tiotropium for M3 
over M2 receptors may decrease the potential for cardiac side 
effects. Early in vivo studies in mice demonstrated that acli-
dinium did not produce mydriasis, as did all other muscarinic 
antagonists tested, including ipratropium and tiotropium.16 
In phase I studies in humans, aclidinium had no significant 
effect on heart rate or QTc interval at doses up to 800 µg.32,33 
Adverse events in human studies encompassing phases I 
through III have been relatively infrequent and generally 
mild.33–38 None of the studies reported serious adverse events 
that were thought to be related to study drug. Nonserious 
adverse events were generally comparable in incidence to 
placebo, and included headache, dry mouth, cough, sore 
throat, upper respiratory tract infection, diarrhea, myalgias, 
and arthralgias. In particular, the incidence of anticholinergic 
side effects in the Phase III study was very low and not sig-
nificantly different from placebo.36 Importantly, in an early 
safety study in healthy subjects, the maximum tolerated dose 
of aclidinium could not be calculated because there were no 
limiting adverse events in $50% of subjects at any dose up 
to as high as 6000 µg and no serious adverse events.39
Efficacy
In preclinical studies, aclidinium not only caused bron-
chodilation and protected against cholinergic-induced 
bronchoconstriction,16–18,28 but also decreased carbachol and 
tobacco smoke-induced overexpression of MUC5 AC,40 a 
mucin that is expressed in greater amounts in the goblet cells International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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of COPD patients relative to healthy subjects.41,42   Further, 
in a murine model of allergen-induced airway hyperre-
sponsiveness, aclidinium completely abrogated increases 
in methacholine-induced lung resistance in mice exposed 
to Aspergillus fumigatus.43 In this same study, aclidinium 
attenuated A. fumigatus-induced increases in total protein 
and eosinophil counts in bronchoalveolar lavage fluid, with 
no significant effects on the trafficking of other leukocytes. 
The authors postulated that this effect may be mediated by 
inhibition of methacholine-induced changes in vascular per-
meability or possibly via inhibition of eosinophil chemotaxis. 
Interestingly, emerging evidence suggests that acetylcholine 
may mediate important effects on immune function via 
muscarinic receptors expressed on non-neuronal cells such 
as airway macrophages, neutrophils, lymphocytes, bronchial 
epithelium, and endothelial cells.44,45 These non-neuronal 
effects of acetylcholine may be more pronounced in COPD, 
where cells from induced sputum of COPD subjects show 
increased expression of M1 and M3 receptors relative to 
those of healthy controls.46 In this same study, acetylcholine 
significantly increased leukotriene B4 release and neutrophil 
chemotactic activity in sputum cells from COPD subjects, but 
not in those from healthy smokers and healthy   nonsmokers. 
Whether anticholinergic therapy may have important ben-
eficial effects on the immune system, however, remains a 
matter of speculation.
Numerous human clinical trials of aclidinium have pro-
vided data regarding its efficacy (see Table 1 for summary). 
In a randomized, double-blind, incomplete crossover Phase I 
study, Schelfhout et al randomized 12 healthy male subjects 
to treatment with single doses of aclidinium (50, 300, or 
600 µg) or placebo with a minimum six-day washout period 
between doses.33 All subjects enrolled were required to dem-
onstrate responsiveness to methacholine challenge, defined 
as a $35% decrease in specific airway conductance with a 
methacholine concentration ,32 mg/mL. All three doses of 
aclidinium yielded statistically significant protection against 
methacholine-induced bronchoconstriction, with the 300 and 
600 µg doses having a greater effect than the 50 µg dose.
The first trial of aclidinium in subjects with COPD 
was a two-center, randomized, double-blind, placebo-
controlled, ascending single-dose, crossover trial conducted 
by Joos et al,37 in which 17 male patients with moderate 
to severe COPD (forced expiratory volume in one second 
[FEV1] ,65% predicted with bronchodilator reversibil-
ity .12% and 200 mL) were randomized to 100, 300, or 
900 µg aclidinium or matching placebo. All doses of acli-
dinium resulted in statistically significant improvements in 
area under the 24-hour FEV1 curve (FEV1 AUC 0–24) compared 
with baseline (147 mL for 100 µg [P = 0.005], 211 mL for 
300 µg [P , 0.0001], and 186 mL for 900 µg [P = 0.0005], 
versus −24 mL for placebo). Although the 300 µg and 
900 µg doses of aclidinium yielded statistically significant 
increases in FEV1 as early as 15 minutes post-dose (122 mL 
for 300 µg [P = 0.002] and 178 mL for 900 µg [P = 0.008]), 
these early differences were likely not clinically significant. 
All doses of aclidinium achieved clinically and statistically 
significant improvements in FEV1 compared with baseline 
by two hours post-dose (234 mL [17.2%] for 100 µg, 344 mL 
[23.3%] for 300 µg, and 377 mL [21.4%] for 900 µg). These 
differences were comparable with those seen in a similar 
study of tiotropium.47
A Phase II trial conducted by Vestbo et al evaluated the 
rate of onset of bronchodilation with aclidinium compared 
with tiotropium and placebo.48 This multicenter, double-blind, 
placebo-controlled, crossover study enrolled 115 COPD 
subjects with an FEV1 between 30% and 60% predicted and 
compared serial spirometry after single doses of aclidinium 
200 µg, tiotropium 18 µg, or placebo. At 30 minutes, 49.5% 
of patients receiving aclidinium had at least a 10% increase 
relative to baseline in FEV1, compared with 51.8% for 
tiotropium and 13.8% for placebo (P , 0.001 for both drugs 
compared with placebo). In addition, the mean percentage 
increase in FEV1 from baseline to 30 minutes was greater 
for aclidinium and tiotropium than for placebo (12%, 11%, 
and 3%, respectively, P , 0.0001).
Chanez et al conducted a multicenter, randomized, 
double-blind, placebo-controlled, Phase IIb study in 464 male 
and female subjects with COPD having an FEV1 of 30%–65% 
of predicted.34 Subjects were randomized to once-daily treat-
ment with aclidinium at doses of 25, 50, 100, 200, or 400 µg, 
matching placebo, or open-label tiotropium 18 µg for a total 
of four weeks of treatment. Aclidinium was associated with 
statistically significant improvements at day 29 in trough FEV1 
relative to placebo (148 mL for 200 µg [P = 0.006], 128 mL 
for 400 µg [P = 0.018]). These improvements were slightly 
less than that for open-label tiotropium (161 mL [P = 0.003]), 
but the improvements in peak FEV1 at day 29 were more 
comparable (202 mL for aclidinium 200 µg [P , 0.001], 
204 mL for aclidinium 400 µg [P , 0.001], and 215 mL for 
tiotropium [P , 0.001]). In keeping with preclinical studies 
suggesting a faster onset of action for aclidinium relative to 
tiotropium,17,19 this study demonstrated a time to peak FEV1 
of two hours for aclidinium 200 µg compared with three 
hours for tiotropium at day 29. Although the authors reported 
clinically significant improvements in disease-related quality International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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of life ($4 points improvement in St George’s Respiratory 
Questionnaire49) ranging from 53% in the aclidinium 400 µg 
group and 64% in the aclidinium 100 µg group, they did not 
provide any data on corresponding improvements among 
those in the placebo or tiotropium groups, making conclu-
sions about improvements in quality of life impossible.
Maltais et al published a multicenter, randomized, 
double-blind, placebo-controlled Phase III trial.38 In this 
study, 181 subjects with moderate to severe COPD (FEV1 
between 30% and 80% predicted with a functional residual 
capacity $120% predicted) were randomized to aclidinium 
200 µg or placebo administered once daily for six weeks. 
At screening, all subjects underwent symptom-limited cycle 
ergometry with increasing workload in 10 W increments in 
order to determine the maximum tolerated workload (Wmax). 
The primary endpoint for the study was change from baseline 
in exercise endurance as measured by duration of exercise 
at a constant work rate of 75% Wmax. Subjects receiving 
aclidinium 200 µg had significantly greater improvements in 
exercise endurance relative to placebo (mean ± standard error 
of 129 ± 31 sec for aclidinium versus 13 ± 31 sec for placebo; 
difference 116 ± 40 sec, P = 0.004). Although the minimum 
clinically important difference in duration of constant work 
rate cycle ergometry is not definitively established, this 
improvement does exceed the proposed minimum clinically 
important difference of 105 seconds50 and is comparable with 
the improvements seen in similar studies with tiotropium51,52 
and a fluticasone-salmeterol combination.53 At the end of the 
six-week trial, subjects randomized to aclidinium were noted 
to have a significant improvement in trough FEV1 relative to 
placebo (difference 101 mL, P , 0.001).
The largest Phase III studies of aclidinium to date were 
recently published jointly by Jones et al.36 The AClidinium 
CLinical trial Assessing efficacy and safety In Moderate to 
severe COPD patients (ACCLAIM/COPD I and ACCLAIM/
COPD II) trials were conducted in Europe and primarily 
North America, respectively. These identical studies were 
randomized, double-blind, placebo-controlled, clinical trials 
randomizing subjects with COPD (FEV1 , 80% predicted) 
in a 3:1 ratio to aclidinium 200 µg or matching placebo once 
daily for 52 weeks. Compared with subjects in ACCLAIM I, 
subjects in ACCLAIM II were slightly older (mean age 65 
versus 62 years), less male-predominant (63% male versus 
79%), and less likely to include current smokers (37% versus 
45%). However, subjects in ACCLAIM II had greater total 
tobacco exposure (58 pack-years versus 39 pack-years) and 
more bronchodilator reversibility (17% versus 12%). Both 
studies enrolled moderate to severe COPD subjects with 
mean FEV1 in both studies of approximately 50%   predicted. 
As in most therapeutic intervention studies, dropout was 
greater in the placebo arms than in the treatment arms 
(21.8% versus 14.2% for ACCLAIM I; 42.2% versus 25.7% 
in ACCLAIM II), but both the overall dropout rate and the 
difference between the treatment and placebo dropout rates 
were greater in ACCLAIM II.
The primary outcome for ACCLAIM I and II was adjusted 
mean trough FEV1 compared with placebo at weeks 12 and 28 to 
fulfill US and European regulatory requirements,   respectively. 
At week 12, ACCLAIM I and II noted mean improvements in 
trough FEV1 over placebo of 61 mL [P , 0.001] and 63 mL 
[P , 0.001], respectively. Week 28 data showed similar 
results, with mean improvements in trough FEV1 compared 
with placebo of 67 mL [P , 0.001] and 59 mL [P , 0.001]. 
Although the improvement in trough FEV1 compared with 
placebo remained significant over the entire 52 weeks of the 
study, the magnitude of improvement was consistently small, 
ranging from 37 mL to 67 mL in ACCLAIM I and from 51 mL 
to 78 mL in ACCLAIM II. These improvements were notably 
smaller than the improvements in trough FEV1 reported in the 
UPLIFT trial of tiotropium.13
In ACCLAIM I, aclidinium treatment was associated 
with a greater likelihood of achieving a clinically significant 
improvement in disease-related quality of life ($4 points 
improvement in St George’s Respiratory Questionnaire49) 
compared with placebo. The magnitude of this benefit was 
preserved throughout the duration of the study and remained 
statistically significant at week 52 (48.1% versus 39.5% for 
placebo, P = 0.025). These results were comparable with 
those seen at one year in the UPLIFT trial (49% in the tiotro-
pium group versus 41% in the placebo group, P , 0.001).13 
In contrast, this same quality of life benefit in ACCLAIM 
II was statistically significant at weeks 12, 28, and 44 but 
appeared to decrease in magnitude over time, losing statistical 
significance at 52 weeks (39.0% versus 32.8% for placebo, 
P = 0.074). Similar results were noted for improvements in 
dyspnea as measured by the transitional dyspnea index, with 
ACCLAIM I showing a sustained benefit and ACCLAIM II 
showing decreasing benefit over time with loss of statistical 
significance.
This difference in quality of life and dyspnea out-
comes between ACCLAIM I and II may be explained 
by the fact that the overall dropout rate in ACCLAIM II 
was much higher than in ACCLAIM I, as was the differ-
ence in dropout between the treatment and placebo arms 
(25.7% in the aclidinium arm and 42.2% in the placebo 
arm of ACCLAIM II, versus 14.2% in the aclidinium International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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arm and 21.8% in the placebo arm of ACCLAIM I). This 
  differential dropout may have biased differences in quality 
of life and dyspnea toward the null hypothesis, especially 
given that the most common reason given for dropout in 
the placebo arm of ACCLAIM II was lack of efficacy 
(17.6% of dropouts compared with 6.7% of dropouts in 
the aclidinium arm). As the authors note, the percentage 
of placebo-treated patients with an improvement of $4 
points in the St George’s Respiratory Questionnaire 
increased over time in ACCLAIM II (from 24.1% to 
32.8%), whereas it remained more constant in ACCLAIM 
I (24.1% to 32.8%). Although the UPLIFT trial (n = 5993, 
with 1:1 randomization) had a much greater power to 
detect a statistically significant difference in quality of 
life compared with the ACCLAIM II trial (n = 804, with 
3:1 treatment to placebo randomization), it should be 
noted that the magnitude of the difference at one year in 
the UPLIFT trial was greater than that seen in ACCLAIM 
II, and UPLIFT had similar differential dropout (37% 
in the tiotropium arm and 45% in the placebo arm). As 
such, the difference in quality of life outcomes between 
the ACCLAIM II and UPLIFT trials cannot be attributed 
to differences in power alone.
In ACCLAIM II, fewer subjects in the aclidinium group 
suffered moderate or severe exacerbations compared with 
those in the placebo group (32.2% versus 39.8%, respec-
tively, P = 0.005). In addition, aclidinium significantly 
delayed the time to first moderate or severe exacerbation 
compared with placebo (hazard ratio 0.7, 95% confidence 
interval [CI] 0.55–0.92]; P = 0.01). However, in ACCLAIM 
I, there was no difference in the rate of moderate or severe 
exacerbations between the aclidinium and placebo arms 
(26.6% versus 25.7%, respectively), and the time to first 
moderate or severe exacerbation was the same in both 
groups (hazard ratio 1.0, 95% CI 0.72–1.33; P = 0.9). 
These differing results may be explained by differences in 
exacerbation rates between the two studies. In ACCLAIM I, 
the placebo group experienced only 0.46 events per subject 
per year compared with 0.80 events per subject per year in 
the placebo group of ACCLAIM II. The exacerbation rates 
in ACCLAIM II were more similar to those in the UPLIFT 
trial, where the placebo group experienced 0.85 events per 
patient per year and there was a similar reduction in exac-
erbations with treatment.13
Conclusion
Aclidinium bromide is a safe and well tolerated anti-
cholinergic bronchodilator with a relatively rapid onset 
and a sufficient duration of action to provide once-daily 
dosing. The kinetic selectivity for M3 over M2 muscar-
inic receptors and rapid plasma hydrolysis of aclidinium 
bromide into inactive metabolites suggest a low potential 
for extrapulmonary side effects that has so far been sup-
ported by clinical trials. Aclidinium achieves its peak 
improvement in FEV1 slightly faster than tiotropium, but 
the magnitude of improvement is similar for both drugs. 
Recent Phase III clinical trials showed a statistically sig-
nificant improvement in trough FEV1 relative to placebo, 
but the magnitude of benefit was somewhat less than that 
seen in clinical trials of tiotropium and earlier Phase II 
trials of aclidinium. Phase III trials have also suggested 
possible improvements in exercise tolerance and qual-
ity of life, but these benefits have not been consistent 
across studies. Overall, aclidinium shows some potential 
for benefit in the treatment of COPD, but whether these 
benefits will meet the threshold for approval by the US 
Food and Drug Administration remains to be seen.
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